Published in Biochem Pharmacol on April 15, 1980
Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal antiinflammatory agents. Proc Natl Acad Sci U S A (1981) 0.90
Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition. J Clin Invest (1981) 0.78
The low dose aspirin controversy solved at last? Br Med J (Clin Res Ed) (1985) 0.77
Acetylsalicylic Acid in migraine with aura prevention - a retrospective study. Curr Health Sci J (2014) 0.75
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet (2001) 6.38
Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem (1999) 3.81
Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet (1978) 3.15
Moderate alcohol use and health: a consensus document. Nutr Metab Cardiovasc Dis (2013) 2.77
Fusion of the human gene for the polyubiquitination coeffector UEV1 with Kua, a newly identified gene. Genome Res (2000) 2.19
Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol (2004) 2.02
Long gamma-ray bursts and core-collapse supernovae have different environments. Nature (2006) 1.88
The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. J Immunol (1986) 1.71
Autoimmunity after induction of neonatal tolerance to alloantigens: role of B cell chimerism and F1 donor B cell activation. J Immunol (1986) 1.54
Gravitational microlensing by low-mass objects in the globular cluster M22. Nature (2001) 1.46
Prostacyclin and human foetal circulation. Prostaglandins (1979) 1.42
The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis (1991) 1.40
The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol (2000) 1.40
[Convulsive symptoms in a young patient]. Rev Clin Esp (2003) 1.39
Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins (1980) 1.33
CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10. J Biol Chem (1999) 1.32
Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost (2006) 1.30
Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem (1998) 1.28
Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet (1982) 1.27
Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res (1979) 1.26
Functional recovery after hematic administration of allogenic mesenchymal stem cells in acute ischemic stroke in rats. Neuroscience (2010) 1.20
Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin. Blood (2001) 1.17
Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain. Eur J Clin Microbiol Infect Dis (2002) 1.16
Dietary patterns, cardiovascular risk factors and C-reactive protein in a healthy Italian population. Nutr Metab Cardiovasc Dis (2009) 1.15
Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res (1977) 1.14
Platelet hyperaggregability and the nephrotic syndrome. Thromb Res (1979) 1.12
Screening for sight threatening diabetic retinopathy using non-mydriatic retinal camera in a primary care setting: to dilate or not to dilate? Int J Clin Pract (2009) 1.10
[Validity of clinical tests to confirm or to exclude the diagnosis of acute appendicitis]. Med Clin (Barc) (2000) 1.10
Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol (1998) 1.09
Bleeding time in laboratory animals. III - Do tail bleeding times in rats only measure a platelet defect? (the aspirin puzzle). Thromb Res (1979) 1.09
Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol (1990) 1.08
[Validity of clinical tests to confirm or exclude the diagnosis of acute myocardial infarction]. Med Clin (Barc) (2000) 1.08
In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome. J Immunol (1990) 1.08
Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost (2001) 1.07
Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J Biol Chem (1998) 1.07
Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thromb Res (1979) 1.05
Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet (1981) 1.05
Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost (1982) 1.05
Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med (1986) 1.04
Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost (1994) 1.03
Indomethacin and urinary excretion of fibrinogen-like material in proliferative glomerulonephritis. Rev Eur Etud Clin Biol (1970) 1.00
Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol (1979) 0.99
Typical breakfast food consumption and risk factors for cardiovascular disease in a large sample of Italian adults. Nutr Metab Cardiovasc Dis (2010) 0.98
Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract (2006) 0.98
Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost (2007) 0.98
Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest (1987) 0.96
Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest (1983) 0.95
Autoimmune syndrome after induction of neonatal tolerance to alloantigens: effects of in vivo treatment with anti-T cell subset monoclonal antibodies. J Immunol (1987) 0.95
Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron (1978) 0.95
2-Substituted-3-oxoisothiazolo[5,4-b]pyridines as potential central nervous system and antimycobacterial agents. Farmaco (1998) 0.95
Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thromb Res (1978) 0.95
Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract (2007) 0.95
Normal prostacyclin-like activity in vascular tissues from thrombocytopenic rats. Thromb Res (1977) 0.95
Quantification and characterization of carotid calcium with multi-detector CT-angiography. Eur J Vasc Endovasc Surg (2006) 0.94
Aspirin, thromboxane, and prostacyclin in rats: A dilemma resolved? Lancet (1978) 0.94
Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis (2011) 0.94
Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol (1979) 0.94
[The validity of 6 indirect methods for assessing drug treatment compliance in arterial hypertension]. Aten Primaria (1997) 0.93
Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost (1978) 0.92
The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb (1992) 0.92
[Undergraduate training in primary health care: 6 years' experience at the University of Alicante]. Aten Primaria (1993) 0.92
Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb Haemost (1981) 0.92
Bleeding in renal failure: is von Willebrand factor implicated? Br Med J (1977) 0.91
Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens. J Immunol (1991) 0.90
Warfarin enantiomers, anticoagulation, and experimental tumour metastasis. Lancet (1978) 0.90
Prostacyclin generation by cultured endothelial cells in haemolytic uraemic syndrome. Lancet (1980) 0.90
Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an oestrogen-progestagen combination. Thromb Res (1979) 0.90
Moderate doses of aspirin and risk of bleeding in renal failure. Lancet (1986) 0.90
Therapeutic effect of early thymic irradiation in (NZB x NZW)F1 mice, associated with a selective decrease in the levels of IgG3 and gp70-anti-gp70 immune complexes. Cell Immunol (1995) 0.89
Prostacyclin-like activity in rat vascular tissues. Fast, long-lasting inhibition by treatment with lysine acetylsalicylate. Prostaglandins (1977) 0.89
Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost (2006) 0.89
Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet (1982) 0.89
Prevalence of deficits of complement components in patients with recurrent meningococcal infections. J Infect Dis (1983) 0.89
Suloctidil: a novel inhibitor of platelet aggregation in human beings. Thromb Res (1976) 0.89
The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. Ital Heart J (2001) 0.89
Synthesis and pharmacological screening of some N-(4-substituted-piperazin-1-ylalkyl)-3,4-pyrroledicarboximides. Farmaco (1999) 0.89
Igh-C allotype-linked control of anti-DNA production and clonotype expression in mice infected with Plasmodium yoelii. J Immunol (1988) 0.89
Prostacyclin-like activity and bleeding in renal failure. Lancet (1977) 0.88
Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins (1982) 0.88
Prostacyclin (PGI2) and bleeding time in uremic patients. Thromb Res (1977) 0.88
Skin fibroblasts from a patient with Glanzmann's thrombasthenia do not induce fibrin clot retraction. Thromb Res (1977) 0.88
The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int (1984) 0.88
P-selectin-beta 2-integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost (1999) 0.88